AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

suramab, a new pharmaceutical compound with antiangiogenic effects

Summary

Suramab is the brand name of a new combination of drugs made up of suramin and bevacizumab. Suramab has antiangiogenic properties that can be applied to oncological and ophthalmological diseases.

The european patent (EP 2186529 B1) was granted in March 2012.

The US patent is still pending

This can be seen in the patent file

Type of Cooperation

License agreement

Supplementary Information

Patent Number: CN100446394C
Application Number: CN2002800104A
Inventor: Zhubang Liao | Minxi Pang | Yijie Pan
Priority Date: 17 Jan 2001
Priority Number: CN100446394C
Application Date: 11 Jan 2002
Publication Date: 24 Dec 2008
IPC Current: H02M0003335 | H02M000100 | H02M000142 | H02M0007155
Assignee Applicant: The University of Hong Kong
Title: High-efficiency AC-DC converter with power factor corrector | Alternating direct current converter with power factor corrector
Usefulness: High-efficiency AC-DC converter with power factor corrector | Alternating direct current converter with power factor corrector
Summary: To enable control of switching and allow operation in soft switching mode.
Novelty: Power converter with power factor correction and which incorporates zero voltage switching

Industry

Biomedical

Sub Group

Medical Cosmetics

Application No.

MX2008000104

Classes

Issued patent

Coverage Areas

Great Britain, Ireland, Sweden, Denmark, The Netherland, Germany, Spain, France

Patent Information

to be negotiated

Country/Region

Argentina

For more information, please click Here